[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515947":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":55,"centralContacts":60,"locations":65,"responsibleParty":89,"collaborators":92,"id":96,"slug":54,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":54,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":54,"enrollmentInfo":104,"targetDuration":54,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":54,"overallStatus":67,"whyStopped":54,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Emory University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (atovaquone)","EXPERIMENTAL","Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.",[13,14,15,16],"Drug: Atovaquone","Procedure: Biopsy","Procedure: Computed Tomography","Procedure: Paracentesis",[18,28,36,50],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Atovaquone","Given PO",[9],[24,25,26,27],"566C80","BW-566C","BW-A566C","Mepron",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"PROCEDURE","Biopsy","Undergo biopsy",[9],[34,35],"BIOPSY_TYPE","Bx",{"type":29,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Computed Tomography","Undergo CT",[9],[41,42,43,44,45,46,47,48,49],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","CT","CT Scan","tomography",{"type":29,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Paracentesis","Undergo paracentesis",[9],null,[56],{"name":57,"affiliation":58,"role":59},"Namita Khanna, MD, MSPH","Emory University Hospital\u002FWinship Cancer Institute","PRINCIPAL_INVESTIGATOR",[61],{"name":57,"role":62,"phone":63,"phoneExt":54,"email":64},"CONTACT","404-778-3401","namita.khanna@emory.edu",[66],{"facility":58,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"RECRUITING","Atlanta","Georgia","30322","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-84.38798,33.749,{"lat":77,"lon":76},[80,84,88],{"name":81,"role":62,"phone":82,"phoneExt":54,"email":83},"Nina Kimball","404-778-8145","nina.cathleen.dobbs.kimball@emory.edu",{"name":85,"role":62,"phone":86,"phoneExt":54,"email":87},"Maisey S Ratcliffe","404-778-3449","maisey.shannon.ratcliffe@emory.edu",{"name":57,"role":59,"phone":54,"phoneExt":54,"email":54},{"type":59,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"Namita Khanna","Principal Investigator",[93],{"name":94,"class":95},"National Cancer Institute (NCI)","NIH","100515947",false,"NCT05998135","Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer","Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer","Inclusion Criteria:\n\n* Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy\n* Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* There will be no limitations on number of prior lines of therapy\n* Trial is open to non-English speaking patients\n* Trial is open to patients referred from community practice\n\nExclusion Criteria:\n\n* Patients who are \\\u003C 18 years old\n* Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)\n* Patients who are incarcerated\n* Patients who are unable to provide consent \u002F lack decision-making capacity","FEMALE","18 Years",{"count":105,"type":106},28,"ESTIMATED","INTERVENTIONAL",[109],"PHASE2","This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.",[112,113],"Ovarian High Grade Serous Adenocarcinoma","Platinum-Resistant Ovarian Carcinoma","2025-09-05",{"date":116,"type":117},"2025-09-11","ACTUAL",{"date":119,"type":117},"2023-11-09",{"date":121,"type":106},"2027-06-30",{"name":5,"class":6},1]